| 2025-12-12 |
详情>>
内部人交易：
STONE HEISZ LESLIE等共交易6笔
|
| 2025-11-05 |
详情>>
股本变动：
变动后总股本58030.00万股
|
| 2025-11-05 |
详情>>
业绩披露：
2025年三季报(累计)每股收益1.68美元,归母净利润9.82亿美元,同比去年增长-74.07%
|
| 2025-10-30 |
财报披露：
美东时间 2025-10-30 盘后发布财报
|
| 2025-08-06 |
详情>>
业绩披露：
2025年中报每股收益1.18美元,归母净利润6.91亿美元,同比去年增长-3.76%
|
| 2025-05-06 |
详情>>
业绩披露：
2025年一季报每股收益0.61美元,归母净利润3.58亿美元,同比去年增长1.73%
|
| 2025-03-26 |
股东大会：
将于2025-05-08召开股东大会
会议内容 ▼▲
- 1.Election of nine director nominees named in the attached Proxy Statement to serve until our next annual meeting of stockholders and until their respective successors are duly elected and qualified
2.Approval, on an advisory basis, of the named executive officer compensation disclosed in the attached Proxy Statement
3.Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025
4.Approval of the Amendment and Restatement of the Company’s 2001 Employee Stock Purchase Plan for United States Employees (the “U.S. ESPP”) to Increase the Total Number of Shares of Common Stock Available for Issuance under the U.S. ESPP by 4,200,000 Shares
5.Approval of the Amendment and Restatement of the Company’s 2001 Employee Stock Purchase Plan for International Employees (the “International ESPP”) to Increase the Total Number of Shares of Common Stock Available for Issuance under the International ESPP by 1,460,000 Shares
6.Other business as may properly come before the Annual Meeting, and any postponement or adjournment of the Annual Meeting
|
| 2025-02-28 |
详情>>
业绩披露：
2022年年报每股收益2.46美元,归母净利润15.22亿美元,同比去年增长1.25%
|
| 2025-02-28 |
详情>>
业绩披露：
2024年年报每股收益6.98美元,归母净利润41.75亿美元,同比去年增长197.68%
|
| 2024-11-06 |
详情>>
业绩披露：
2024年三季报(累计)每股收益6.31美元,归母净利润37.89亿美元,同比去年增长266.97%
|
| 2024-07-31 |
详情>>
业绩披露：
2023年中报每股收益1.07美元,归母净利润6.48亿美元,同比去年增长-16.97%
|
| 2024-07-31 |
详情>>
业绩披露：
2024年中报每股收益1.19美元,归母净利润7.18亿美元,同比去年增长10.90%
|
| 2024-04-29 |
详情>>
业绩披露：
2024年一季报每股收益0.58美元,归母净利润3.52亿美元,同比去年增长3.35%
|
| 2024-03-26 |
股东大会：
将于2024-05-07召开股东大会
会议内容 ▼▲
- 1.Election of eight director nominees named in the attached Proxy Statement to serve until our next annual meeting of stockholders and until their respective successors are duly elected and qualified
2.Approval, on an advisory basis, of the named executive officer compensation disclosed in the attached Proxy Statement
3.Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024
4.Approval of the amended and restated Long-Term Stock Incentive Compensation Program
5.Other business as may properly come before the Annual Meeting, and any postponement or adjournment of the Annual Meeting
|
| 2024-02-12 |
详情>>
业绩披露：
2023年年报每股收益2.31美元,归母净利润14.02亿美元,同比去年增长-7.85%
|
| 2023-10-27 |
详情>>
业绩披露：
2023年三季报(累计)每股收益1.70美元,归母净利润10.32亿美元,同比去年增长-8.1%
|
| 2023-03-28 |
股东大会：
将于2023-05-11召开股东大会
会议内容 ▼▲
- 1.Election of nine director nominees named in the attached Proxy Statement to serve until our next annual meeting of stockholders and until their respective successors are duly elected and qualified
2.Approval, on an advisory basis, of the named executive officer compensation disclosed in the attached Proxy Statement
3.Approval, on an advisory basis, of the frequency of future advisory votes on the compensation of our named executive officers
4.Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023
5.Approval of an amendment to the Company's Amended and Restated Certificate of Incorporation to provide for exculpation of officers as permitted by the Delaware General Corporation Law
6.Consider a stockholder proposal, if properly presented at the Annual Meeting
7.Other business as may properly come before the Annual Meeting, and any postponement or adjournment of the Annual Meeting
|
| 2022-03-22 |
股东大会：
将于2022-05-03召开股东大会
会议内容 ▼▲
- 1.Election of eight director nominees named in the attached Proxy Statement to serve until our next annual meeting of stockholders and until their respective successors are duly elected and qualified
2.Approval, on an advisory basis, of the named executive officer compensation disclosed in the attached Proxy Statement
3.Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022
4.Consider a stockholder proposal, if properly presented at the Annual Meeting
5.Other business as may properly come before the Annual Meeting, and any postponement or adjournment of the Annual Meeting
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-03-23 |
股东大会：
将于2021-05-04召开股东大会
会议内容 ▼▲
- 1.Election of eight director nominees named in the attached Proxy Statement to serve until our next annual meeting of stockholders and until their respective successors are duly elected and qualified
2.Approval, on an advisory basis, of the named executive officer compensation disclosed in the attached Proxy Statement
3.Approval of the Amendment and Restatement of the Company’s 2001 Employee Stock Purchase Plan for United States Employees (the “U.S. ESPP”) to increase the total number of shares of common stock available for issuance under the U.S. ESPP by 3,300,000 shares
4.Approval of the Amendment and Restatement of the Company’s 2001 Employee Stock Purchase Plan for International Employees (the “International ESPP”) to increase the total number of shares of common stock available for issuance under the International ESPP by 1,200,000 shares
5.Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021
6.Consider two stockholder proposals, if properly presented at the Annual Meeting
7.Other business as may properly come before the Annual Meeting, and any postponement or adjournment of the Annual Meeting
|
| 2020-05-07 |
详情>>
拆分方案：
每1.0000股拆分成3.0000股
|
| 2020-03-25 |
股东大会：
将于2020-05-07召开股东大会
会议内容 ▼▲
- 1.Election of eight director nominees named in the attached Proxy Statement to serve until our next annual meeting of stockholders and until their respective successors are duly elected and qualified
2.Approval, on an advisory basis, of the named executive officer compensation disclosed in the attached Proxy Statement
3.Approval of the 2020 Nonemployee Directors Stock Incentive Program
4.Approval of amendment of the Certificate of Incorporation to increase the number of authorized shares of common stock for the purpose of effecting a three-for-one stock split
5.Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020
6.A stockholder proposal, if properly presented at the Annual Meeting
|
| 2019-03-27 |
股东大会：
将于2019-05-08召开股东大会
会议内容 ▼▲
- 1.Election of eight director nominees named in the attached Proxy Statement to serve until our next annual meeting of stockholders and until their respective successors are duly elected and qualified
2.Approval, on an advisory basis, of the named executive officer compensation disclosed in the attached Proxy Statement
3.Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019
4.A stockholder proposal, if properly presented at the Annual Meeting
|
| 2018-03-29 |
股东大会：
将于2018-05-17召开股东大会
会议内容 ▼▲
- 1.Election of eight director nominees named in the attached Proxy Statement to serve until our next annual meeting of stockholders and until their respective successors are duly elected and qualified
2.Approval, on an advisory basis, of the named executive officer compensation disclosed in the attached Proxy Statement
3.Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018
4.A stockholder proposal, if properly presented at the Annual Meeting
5.Any other business that may properly come before the Annual Meeting or any postponement or adjournment of the meeting
|
| 2017-03-30 |
股东大会：
将于2017-05-11召开股东大会
会议内容 ▼▲
- 1.To elect the eight nominees identified in the attached proxy statement (the "Proxy Statement") as directors to serve until the 2018 annual meeting of stockholders and until their respective successors are elected and qualified;
2.To approve, on an advisory basis, the frequency of named executive officer compensation votes;
3.To approve, on an advisory basis, named executive officer compensation;
4.To approve an amendment and restatement of the Company's Long-Term Stock Incentive Compensation Program (the "Long-Term Stock Program") to increase the total number of shares of common stock available for issuance under the Long-Term Stock Program by 1,400,000 shares;
5.To approve an amendment and restatement of the Company's 2001 Employee Stock Purchase Plan for United States Employees (the "U.S. ESPP") to increase the total number of shares of common stock available for issuance under the U.S. ESPP by 1,500,000 shares;
6.To ratify the appointment of PricewaterhouseCoopers LLP ("PwC") as the Company's independent registered public accounting firm for the year ending December 31, 2017;
7.To transact such other business as may properly come before the Annual Meeting.
|
| 2016-03-31 |
股东大会：
将于2016-05-12召开股东大会
会议内容 ▼▲
- 016 Annual Meeting of Stockholders (the "Annual Meeting") of Edwards Lifesciences Corporation, a Delaware corporation (the "Company"), will be held at the corporate headquarters of the Company, located at One Edwards Way, Irvine, California 92614 on Thursday, May 12, 2016, at 10:00 a.m., Pacific Daylight Time, for the following purposes:
1.To elect the eight nominees identified in the attached proxy statement (this "Proxy Statement") as directors to serve until the 2017 annual meeting of stockholders and until their respective successors are elected and qualified;
2.To approve, on an advisory basis, the compensation of the Company's Named Executive Officers;
3.To approve an amendment and restatement of the Company's Long-Term Stock Incentive Compensation Program (the "Long-Term Stock Program") to, among other things, increase the total number of shares of common stock available for issuance under the Long-Term Stock Program by 2,000,000 shares;
4.To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2016;
5.To transact such other business as may properly come before the Annual Meeting.
|
| 2015-11-19 |
详情>>
拆分方案：
每1.0000股拆分成2.0000股
|
| 2015-03-30 |
股东大会：
将于2015-05-14召开股东大会
会议内容 ▼▲
- 1.To elect the five nominees identified in the attached proxy statement (this "Proxy Statement") as directors for the terms described therein;
2.To approve, on an advisory basis, the compensation of the Company's Named Executive Officers;
3.To approve the 2015 Edwards Incentive Plan in accordance with Internal Revenue Code 162(m), as required every five years;
4.To approve an amendment and restatement of the Company's Long-Term Stock Incentive Compensation Program (the "Long-Term Stock Program") to, among other things, increase the total number of shares of common stock available for issuance under the Long-Term Stock Program by 2,000,000 shares;
5.To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2015;
6.To consider a stockholder proposal, if properly presented at the Annual Meeting;
7.To transact such other business as may properly come before the Annual Meeting.
|